



Article scientifique

Article

2018

Published version

Open Access

This is the published version of the publication, made available in accordance with the publisher's policy.

Health Outcomes for Clients of Needle and Syringe Programs in Prisons

Lazarus, Jeffrey V; Safreed-Harmon, Kelly; Hetherington, Kristina L; Bromberg, Daniel J; Ocampo, Denise; Graf, Niels; Dichtl, Anna; Stöver, Heino; Wolff, Hans

How to cite

LAZARUS, Jeffrey V et al. Health Outcomes for Clients of Needle and Syringe Programs in Prisons. In: Epidemiologic Reviews, 2018, vol. 40, n° 1, p. 96–104. doi: 10.1093/epirev/mxx019

This publication URL: <https://archive-ouverte.unige.ch/unige:155749>

Publication DOI: [10.1093/epirev/mxx019](https://doi.org/10.1093/epirev/mxx019)

Health Outcomes for Clients of Needle and Syringe Programs in Prisons

Jeffrey V. Lazarus*, Kelly Safreed-Harmon, Kristina L. Hetherington, Daniel J. Bromberg, Denise Ocampo, Niels Graf, Anna Dichtl, Heino Stöver, and Hans Wolff

*Correspondence to Prof Jeffrey V. Lazarus, Barcelona Institute for Global Health (ISGlobal), Calle Roselló 132, ES-08036 Barcelona Spain (e-mail: Jeffrey.Lazarus@isglobal.org).

Accepted for publication November 22, 2017.

High levels of drug dependence have been observed in the prison population globally, and the sharing of injecting drug equipment in prisons has contributed to higher prevalence of bloodborne diseases in prisoners than in the general population. Few prison needle and syringe programs (PNSPs) exist. We conducted a systematic review to assess evidence regarding health outcomes of PNSPs. We searched peer-reviewed databases for data relating to needle and syringe programs in prisons. The search methodology was conducted in accordance with accepted guidelines. Five studies met review inclusion criteria, and all presented evidence associating PNSPs with one or more health benefits, but the strength of the evidence was low. The outcomes for which the studies collectively demonstrated the strongest evidence were prevention of human immunodeficiency virus and viral hepatitis. Few negative consequences from PNSPs were observed, consistent with previous evidence assessments. More research is needed on PNSP effectiveness, and innovative study designs are needed to overcome methodological limitations of previous research. Until stronger evidence becomes available, policymakers are urged to recognize that not implementing PNSPs has the potential to cause considerable harm, in light of what is currently known about the risks and benefits of needle and syringe programs and PNSPs and about the high prevalence of human immunodeficiency virus and viral hepatitis in prisons.

bloodborne pathogens; drug use; harm reduction; hepatitis, viral, human; HIV; needle-exchange programs; prisons; review, systematic

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; NSP, needle and syringe program; PNSP, prison needle and syringe program; PWID, people who inject drugs; WHO, World Health Organization.

INTRODUCTION

There are 10 million people in prisons worldwide, and high levels of drug dependence have been observed in prison populations (1, 2). Some people who injected drugs before they were incarcerated continue to do so while in prison, whereas other people initiate injecting drug use in prison (2–4). In studies in Australia, England, the Netherlands, and Thailand, the proportions of inmates who reported injecting drugs while in prison were 52%, 12%, 3%, and 25%, respectively (2).

Health consequences of injecting drug use include exposure to bloodborne viruses as a result of sharing contaminated injecting equipment, and prison inmates often have higher prevalence of bloodborne diseases than does the general population. According to a 2016 meta-analysis, worldwide prevalence of human immunodeficiency virus (HIV) among prison inmates is 3.8%, and 4.8% of inmates are living with chronic hepatitis B virus (HBV) infection. It was estimated that 15.1% of inmates are positive for

hepatitis C virus (HCV) antibodies, meaning that they have been exposed to HCV but do not necessarily have chronic infection (4). On the basis of findings of another meta-analysis, which focused specifically on HCV in prisons, researchers estimated that more than one-quarter of inmates worldwide are HCV antibody positive (5).

There is less evidence regarding the extent to which people are becoming infected with HIV, HBV, and HCV during periods of incarceration as opposed to acquiring these viruses before entering prison. Furthermore, injecting drug use is only 1 of multiple transmission pathways that are commonly found in prisons; other practices, such as sharing contaminated tattooing equipment, also contribute to the spread of bloodborne viruses among inmates. However, the scarcity of injecting drug equipment in prisons leads to the available equipment being widely shared, and major outbreaks of HIV in several countries have been linked to injecting drug use among inmates (2, 6, 7). Researchers also

have documented new HCV infections attributable to injecting drug use among inmates (8).

In 1983, the Amsterdam Health Department initiated the world's first government-run needle and syringe program (NSP) for people who inject drugs (PWID). Although preventing HBV transmission among PWID was the immediate concern, health officials soon recognized NSP as a strategy for responding to the emerging HIV epidemic (9). After the documented success of the Amsterdam NSP, similar programs were implemented in Australia, the United Kingdom, and the United States (10).

Several systematic reviews of NSP research have been published. In a 2017 overview of systematic reviews, Fernandes et al. (11) focused on assessing evidence of the effectiveness of NSPs in reducing the spread of bloodborne infections among PWID. They excluded evidence drawn solely from prison populations, in light of their assessment that prison and nonprison populations have distinct characteristics. They found some review-level evidence that NSPs reduce HIV transmission among PWID. Findings were mixed regarding whether NSPs reduce HCV transmission. The researchers concluded that evidence relating to the effect of NSPs is highly heterogeneous and of low methodological quality overall (11). Davis et al. (12) made a similar observation in a systematic review and meta-analysis focusing specifically on HCV risk. Among the 6 studies that met their review criteria, pooled hazard ratios from 4 studies indicated that NSPs had a statistically significant harmful effect in terms of the association between NSP use and HCV seroconversion, whereas pooled risk ratios from 2 studies indicated that NSP participation had no effect. The authors concluded that the existing empirical evidence was not sufficient to either recommend or discount NSPs as an HCV prevention strategy (12). In a Cochrane systematic review that only included studies comparing multiple study arms, 7 studies collectively provided weak evidence associating high NSP coverage with a lower risk of HCV acquisition (13).

Nonetheless, on the basis of what is known about the potential benefits of NSPs, the World Health Organization (WHO) and other major public-health stakeholders have strongly endorsed this intervention, as have harm reduction service providers and members of communities affected by injecting drug use (14–16). As of 2016, 90 countries were reported to have at least 1 operational NSP (17). At the same time, concerns have been raised about whether the existing evidence is strong enough to justify the intervention. Designing and executing scientifically robust research to investigate the efficacy and effectiveness of NSPs, whether in community or prison settings, is fraught with challenges—from losing study participants to follow-up to the limited generalizability of findings due to nonprobabilistic sampling methodologies.

The international community has recognized the principle of equivalence in relation to the treatment of prisoners, meaning that governments have the obligation to provide prisoners with the same level of care that is available to the nonprison population. In 1990, the United Nations General Assembly adopted a resolution that committed Member States to providing prisoners with “access to the health services available in the country without discrimination on the grounds of their legal situation” (18, p. 1). In 1993, in a recommendation addressing HIV in prisons, the Council of Europe similarly pronounced that “respect for the fundamental rights of prisoners, in particular the right to health care, entails the provi-

sion to prisoners of preventive treatment and health care equivalent to those provided to the community in general” (19, p. 1). WHO, the United Nations Office on Drugs and Crime, and the Joint United Nations Programme on HIV/AIDS have further elaborated on governments' responsibilities in relation to the provision of equivalent health care to prisoners, as has the World Medical Association (20, 21).

In 1992, a prison physician in Switzerland initiated the first known prison-based NSP (PNSP) (22, 23). The prison director's support for this activity proved to be atypical, and few other prisons followed suit (24). Harm Reduction International reported that only 8 countries worldwide were providing NSPs in at least 1 prison in 2016: Armenia, Germany, Kyrgyzstan, Luxembourg, Moldova, Spain, Switzerland, and Tajikistan (17). There are reports of pilot PNSPs in other countries such as Iran and Romania (25, 26).

By not implementing PNSPs more widely, governments are disregarding the advice of WHO, which first publicly supported PNSPs in 1993 (27). A landmark technical paper copublished in 2007 by the WHO, Joint United Nations Programme on HIV/AIDS, and the United Nations Office on Drugs and Crime presented a thorough assessment of the available evidence on PNSPs. The body of evidence as a whole had major methodological limitations, including extensive reliance on descriptive findings from evaluation studies. Generally, however, it supported the premise that PNSPs reduce the sharing of nonsterile injecting equipment. The dearth of evidence for serious unintended negative consequences of PNSPs was noted as well. According to WHO, opposing the implementation of PNSPs on the grounds of incomplete scientific evidence would be considered “both poor scientific judgment and bad public health policy” (8, p. 18, 28). Although they acknowledged that more evidence was needed, WHO and the other agencies concluded that on the basis of what was then known, “[p]rison authorities in countries experiencing or threatened by an epidemic of HIV infections among (injecting drug users) should introduce needle and syringe programs urgently and expand implementation to scale as soon as possible” (8, p. 18). In making the case for PNSPs, they cited the more widely available evidence of the benefits of nonprison NSPs (8).

WHO reiterated the PNSP recommendation in 2014, basing its position on an updated literature review. The 2014 publication, like the 2007 one, noted additional possible benefits of PNSPs beyond reducing HIV transmission. These included reducing the risk of drug overdose and decreasing the incidence of abscesses caused by injecting drugs. Evidence from methodologically rigorous peer-reviewed studies remained quite limited (1).

There has been a sustained global movement to end the HIV epidemic for more than 20 years (29, 30). More recently, growing recognition of the burden of disease from HBV and HCV has led to the emergence of globally coordinated responses to both diseases and, in 2016, WHO introduced the goal of eliminating viral hepatitis “as a major public health threat” by 2030 (31, p. 21). Injecting drug use is a major driver of the transmission of all 3 diseases in prison populations. However, there do not appear to be any systematic reviews of evidence relating to health outcomes of prison-based NSPs. In this article, we seek to fill an important gap in the literature by presenting the first such study.

METHODS

A search was conducted in the following 4 bibliographic databases to identify studies of NSPs in prisons: MEDLINE (via Ovid), Embase (via Ovid), PsycINFO, (via Ovid) and Cumulative Index to Nursing and Allied Health Literature (CINAHL; via EBSCOhost). Each was searched from inception to January 26, 2017. Searches were conducted by combining terms related to prisons or prisoners (e.g., prisons, jail, penitentiary, correctional facility, custody, detainee, incarcerated) and NSPs (e.g., needles, syringes, exchange, provision, distribution, program).

The appropriate indexing terms and free-text searches were applied for each database (Web Appendix 1, available at <https://academic.oup.com/aje>). Results were limited to include only records indexed as involving humans. No language or geographic restrictions were applied, but only articles in English, German, or Spanish were reviewed, because of staff language capacity. After removing duplicates, the titles and abstracts of the remaining records were manually screened to identify potentially relevant studies and to establish types of potential health outcomes. Google Scholar was used to check if the search string had missed any relevant studies.

A study was considered for inclusion if it focused on a PNSP, if the authors had outlined how it was conducted, and if any health outcomes observed as a result of the intervention were reported. Studies that did not aim to measure health outcomes among PWID in prisons but reported them as unintended benefits were also considered for inclusion. Health outcomes were defined as any change in the health status of study participants, including behavioral changes (e.g., reduced risk behavior) and infection rate changes in HIV and/or viral hepatitis. Health outcomes could have been measurable or they could have been self-perceived and self-reported by PNSP clients and/or providers. Studies reporting quantitative and/or qualitative findings on any health-related outcome of these programs were eligible for inclusion. Studies reporting results of PNSP as part of a package of interventions (e.g., harm reduction services) were considered for inclusion if a PNSP-specific subanalysis was conducted. All types of PNSP interventions were considered for inclusion, regardless of the type of needle and syringe distribution mode (e.g., hand-to-hand, vending machine). Original research articles and review articles, systematic or otherwise, were eligible for inclusion. Studies based on surveys, interviews, case studies, ethnographic research, and intervention research were all eligible for inclusion. Articles published as comments, editorials, letters, or narrative reviews were excluded, as were studies that addressed the epidemiology, diagnosis, or treatment of HIV, tuberculosis, hepatitis and/or drug consumption without making reference to PNSPs.

A data extraction template was used and included bibliographic details, study design, intervention, and measureable health outcomes among clients of PNSPs. Two members of the study team reviewed the articles, extracted the data, and compared the findings.

All components of the search methodology were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-Analysis of Observational Studies in Epidemiology guidelines for systematic reviews (32). Study quality was assessed by members of the study team, and limitations to the designs of included studies were noted. Due to the overall lack of studies included in the

review, inconsistent study designs, different levels of measurements, and substantial variation between study settings, a statistical test for heterogeneity was not conducted.

RESULTS

The search yielded 745 records, of which 378 were eliminated because they were duplicates. Title and abstract screening of the remaining 367 articles resulted in the exclusion of 306 articles. All of the remaining 61 articles underwent full-text screening; 5 met the inclusion criteria and were included in the final review (Figure 1). No other studies were identified through an additional Google Scholar search. The studies included in the final analysis were conducted in Germany ($n = 3$), Spain ($n = 1$), and Switzerland ($n = 1$) (Table 1).




Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram showing inclusion criteria. CINAHL, Cumulative Index to Nursing and Allied Health Literature.

Table 1. Studies of Health Outcomes Associated With Prison Needle and Syringe Programs ($n = 5$)

First Author, Year (Reference No.)	Title	Study Design	Target Population(s)	No. of Participants	Intervention	Data Collection Period	Outcomes
Ferrer-Castro, 2012 (33)	Evaluation of a needle exchange program at Pereiro de Aguiar prison (Ourense, Spain): a ten-year experience	Cross-sectional	Male and female prisoners in O Pereiro de Aguiar (Spain)	Baseline: 362 men and women Follow-up: 425 men and women	Hand-to-hand approach used to exchange needles and syringes.	Baseline (1999) and at 10-year follow-up (2009)	HCV prevalence decreased from 40% at baseline to 26% at follow-up. HIV prevalence decreased from 21% at baseline to 8% at follow-up.
Heinemann, 2001 (34)	Infektionsprophylaxe für Drogenkonsumenten im offenen Strafvollzug durch Vergabe steriler Einmalspritzen über Automaten (Prevention of bloodborne virus infections among drug users in an open prison by syringe vending machines)	Mixed methods	Male and female prisoners in Hamburg-Vierlande (Germany)	Before PNSP: 128 During PNSP: 338	Syringe dispensing machines used to distribute needles and syringes.	1996–1997	No new HIV or hepatitis infections No change in knowledge of hepatitis in general, symptoms, disease, or transmission Increased drug consumption, together with methadone
Jacob, 2000 (35)	The transfer of harm-reduction strategies into prisons: needle exchange programs in two German prisons	Mixed methods	Male prisoners in Lingen (Germany) Female prisoners in Vechta (Germany)	83 men 169 women	Hand-to-hand approach used to distribute needles and syringes in Lingen. Syringe dispensing machines used to distribute needles and syringes in Vechta.	1996–1998	Decreased injection-related abscesses (Vechta) Decreased psychological disorders requiring treatment (Vechta) No overdoses occurred in Vechta; 1 overdose occurred in Lingen. No new HIV or hepatitis infections Risk behavior decreased. No change in drug consumption
Nelles, 1998 (37)	Provision of syringes: the cutting edge of harm reduction in prison?	Implementation	Female prisoners in Hindelbank (Switzerland)	137 women	Syringe dispensing machines used to distribute needles and syringes	1994–1995	No new infections of HBV, HCV, or HIV No increased drug consumption 1 case of used-syringe sharing No change in knowledge of HIV and AIDS
Stark, 2006 (38)	A syringe exchange program in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany	Implementation	Prisoners in 1 male-only and 1 female-only prison in Berlin, Germany	Baseline: 57 men, 117 women Follow-up: 43 men, 81 women	Hand-to-hand approach used to distribute needles and syringes via NGO representatives in male-only prison. Syringe dispensing machines used to distribute needles and syringes in female-only prison.	1999–2001 for male cohort 1998–2001 for female cohort	Baseline: HIV, HBV, and HCV seroprevalence rates were 18%, 53%, and 82%, respectively (both cohorts combined). Follow-up: No new HBV or HIV infections in either cohort Follow-up: 1 to 4 HCV infections acquired while in prison (1 during imprisonment; not possible to know if 3 occurred before or during imprisonment)

Abbreviations: AIDS, acquired immunodeficiency syndrome; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; NGO, nongovernmental organization; PNSP, prison needle and syringe program.

Ferrer-Castro et al. (33) tested prisoners in the Pereiro de Aguiar prison in Spain for HBV, HCV, and HIV in 1999, then again in 2009 after the introduction of a hand-to-hand PNSP ($n = 362$ at baseline; $n = 425$ at follow-up). The authors found that HIV prevalence dropped from 21% to 8% ($P \leq 0.01$) and HCV prevalence dropped from 40% to 26% ($P \leq 0.01$). There was no significant change in HBV antibody prevalence, which was already quite low (2%) at baseline.

Between 1996 and 1997, Heinemann et al. (34) conducted a mixed-methods study in a German prison; data were gathered via survey, blood samples, and patient records, including drug consumption patterns. The researchers found no new HIV or hepatitis infections among PWID after the initiation of a PNSP. There was also no change in knowledge of hepatitis and associated risks. An increase in drug consumption among a subset of study participants taking methadone was observed.

In a comparative PNSP pilot study that took place in 1 all-female ($n = 169$) and 1 all-male ($n = 83$) prison in Germany, researchers reported no new HIV or hepatitis infections, an overall reduction in risk behavior, no overdoses at the all-female facility, and 1 overdose at the all-male facility (35, 36). There was a decrease in injecting-related abscesses and a decrease in psychological disorders requiring treatment at the all-female prison. Furthermore, there was no evidence of an increase in drug consumption.

Between 1994 and 1995, researchers conducting a PNSP pilot study in an all-female prison in Switzerland ($n = 137$) observed no new infections of HIV, HBV, or HCV during the study period (37). Likewise, no increased drug use was observed and participants discontinued the sharing of used syringes, except in 1 documented case. However, there was no change in prisoner knowledge of HIV and acquired immunodeficiency syndrome.

Finally, in a PNSP study in Berlin, Germany, HIV, HBV, and HCV seroconversions were measured among PWID in 1 all-male and 1 all-female prison ($n = 174$, both sexes) (38). The baseline seroprevalence for HIV, HBV, and HCV was 18%, 53%, and 82%, respectively. No HIV or HBV seroconversions occurred during follow-up ($n = 124$, both sexes). There were 4 new HCV cases, 3 of which could have occurred either before or during incarceration.

DISCUSSION

This systematic review was conducted to assess the current state of evidence regarding health benefits of PNSPs, an intervention recognized as an important HIV and HCV prevention strategy but rarely implemented in correctional settings worldwide. Although 5 studies identified in our review presented evidence associating PNSPs with 1 or more health benefits, the overall strength of the findings was low. However, the studies collectively indicated that PNSPs appear to contribute to the prevention of HIV, HBV, and HCV transmission among prison inmates. Anecdotal evidence suggested additional benefits, including decreased risk behavior, fewer drug use–related abscesses, decreased incidence of psychological disorders requiring treatment, increased uptake of other harm reduction services, improved infectious disease–related knowledge among inmates, and almost no drug overdoses. There were conflicting findings regarding whether PNSPs was associated with reduced drug consumption among study populations.

Paralleling the findings of 2 nonprison NSP reviews, we found in the present review that methodological weaknesses were common (11, 12). Furthermore, the 5 studies analyzed in this review encompass various study designs, interventions, prison settings, and prison populations. It is also notable that only 2 of the studies were published more recently than 2000. Taken together, these issues make it difficult to draw meaningful conclusions from the studies about the general effectiveness of PNSPs.

This situation likely reflects the inherent difficulty of conducting methodologically robust research on the provision of clean injecting equipment in prisons. High turnover in the prison population in many settings is an obstacle to following large numbers of individuals longitudinally (i.e., the transfer or release of study participants means that they are not available for follow-up unless there is a mechanism for tracking and retaining them in the study). In addition, in some studies in our review, clean needles and syringes were provided along with other interventions such as condom distribution, health education activities, and referral to drug treatment services. This is consistent with evidence-based advice from the United Nations Office on Drugs and Crime and other United Nations agencies to implement PNSPs as part of a comprehensive package of harm reduction services (39). From a scientific standpoint, the simultaneous use of multiple interventions makes it difficult to attribute any observed changes to a specific intervention. From an ethical standpoint, however, it would not be acceptable to conduct a study that gave prison inmates access to 1 intervention but not other interventions that have been shown to have health benefits. Therefore, it is necessary to explore other methodological approaches for assessing the effectiveness of PNSPs.

The question facing policymakers—an urgent question in many settings, in light of the high HIV, HBV, and HCV prevalence in prison populations—is whether to institute PNSPs on the basis of existing knowledge. Typically, evidence-based medical and public health decision-making calls for a convincing demonstration of effectiveness, or, at the minimum, a finding of efficacy in controlled study situations, before new interventions are endorsed as good practices. However, in the context of a public health crisis that health officials are unable to contain, it may be justifiable to implement strategies on the basis of less-than-ideal evidence. For example, when the Thai government targeted all of the nation's sex work establishments with the 100% condom use program to combat HIV in the early 1990s, there was little direct evidence that an intervention of that nature would reduce HIV transmission, and critics of the initiative questioned its feasibility. Thailand went on to experience a sharp decline in new HIV cases, and 100% condom use became recognized as a key factor in enabling the country to avoid a much larger HIV epidemic (40, 41).

The potential risks and benefits of not scaling up a promising intervention need to be considered alongside the potential risks and benefits of taking action. In the case of PNSPs, the provision of clean injecting equipment to PWID outside of prisons is, in fact, considerably more than a promising approach to reducing transmission of bloodborne viruses. There is widespread consensus among diverse stakeholders regarding the beneficial public health impact of NSPs (8). Although it is acknowledged that some of the available evidence does not embody the highest empirical standards in public health research, the perceived

public health gains are of sufficient magnitude to warrant allocating financial and human resources to the provision of this intervention in many settings, and the failure to implement a NSP cannot be justified by the current body of evidence or lack thereof (42). Because clean injecting equipment has the same potential to protect the health of prisoners as it does for nonprisoners, it thus makes sense to provide this intervention unless 1 or more unique features of prison settings present health-related or safety-related concerns.

Opponents of PNSPs have suggested that providing clean injecting equipment to prisoners may result in harmful drug use-related outcomes (43). Not all of the studies identified in our review reported on this issue, but among those that did, researchers generally observed minimal or no harmful drug-use related outcomes. The exception is a 2001 study that found that prisoners on methadone substitution treatment were at a higher risk of taking drugs again after the initiation of a PNSP at a prison in Germany (35). It may be that some context-specific characteristics of prison populations and prison settings result in a different risk-benefit ratio than nonprison settings, and it is important for future studies examining the effect of PNSPs to continue looking for any evidence of harmful drug-use related outcomes in addition to evidence of health benefits (39).

Opponents of PNSPs also have suggested that needles might be used as weapons against other prisoners or staff, or might otherwise cause harm (44). In 1 of the studies in our review, it was reported that neither needles nor syringes were used as weapons; the other studies did not address this issue. In a study that did not meet the review inclusion criteria, correctional officers who participated in an evaluation after 22 months of implementation of a PNSP in Spain reported that prisoners had never used needles as weapons (44). In another study that did not meet review inclusion criteria, researchers showed that the availability of syringes and needles meant that prisoners no longer had to hide them, resulting in fewer injuries when staff conducted cell searches (45). However, authors of an article in our review reported seeing no improvement regarding the number of needles being hidden by inmates after the start of the PNSP (35). Future studies should continue to address this issue because strong observational evidence could be used either to further corroborate the safety of PNSPs or call attention to ways in which they might be improved.

Methodologies for future PNSP studies need to take into account that HCV can survive for a long time outside of the human body. In prison settings, it is not uncommon to share multiple objects that may be contaminated with HCV, such as razors, toothbrushes, and tattooing equipment (46, 47). This has implications for efforts to assess whether PNSPs reduce HCV transmission levels, because transmission can occur through pathways unrelated to injecting drug use. Mixed-methods approaches have the potential to help researchers account for such factors and to document incident cases of HCV in prison settings with greater certainty about transmission pathways.

The paucity of PNSPs worldwide raises the question of whether the stigmatized nature of injecting drug use has contributed to the lack of policy action (48). There does not appear to be any research addressing this issue, but the absence of PNSPs in many countries with high levels of HIV and HCV among prison populations is striking given the strong and consistent recommendations issued by United Nations technical experts. It is particularly notable that WHO's first endorsement of PNSPs came in

1993 and that this agency reiterated its recommendation in favor of PNSPs after a 2014 evidence review (1, 8).

Efforts to overcome political resistance to PNSPs should directly address the issue of stigma and should encourage policymakers and their constituents to consider whether there is any basis in evidence for their concerns about the negative consequences of PNSPs. A related issue is that endorsing PNSPs constitutes a tacit acknowledgment that illegal drugs are circulating in prisons, and government officials may fear criticism for allowing such a situation to exist. Education about substance use disorders and about the factors that lead people with substance use disorders to continue seeking drugs while in prison may help reframe this issue, with PNSP presented as part of a comprehensive package of interventions that address inmates' health needs.

Another policy consideration in relation to inmate health is the legal and human rights principle of equivalence. Where NSPs are available to PWID outside of prisons, as is the situation in 90 countries worldwide, the denial of the same service within prisons violates this principle (17). Again, there is a role for education: Making people more aware of the successful functioning of NSPs in the community, and of their health benefits, can foster an understanding of PNSPs as a necessary aspect of providing inmates with the same health services to which the general population is entitled.

It is also important for policymakers to understand the public health gains that can be achieved by implementing PNSPs. The high prevalence of bloodborne diseases in prison populations, coupled with the frequent movement of some individuals between prison and nonprison settings, may facilitate the spread of these diseases within and outside of prisons (7). Making more headway in regard to prison disease prevention can be expected, therefore, to contribute to lowering disease incidence and prevalence in the community more broadly (8).

Prison-based harm reduction programs are vulnerable to budget restrictions and financial crises. This may be a factor contributing to the absence of PNSPs worldwide. Decreases in contributions allocated for harm reduction services from donors such as The Global Fund have increased the need for improved resource efficiency and alternative funding mechanisms to maintain prison-based interventions such as PNSPs (49). It is unclear how current decreases in government and donor funding have directly affected PNSPs. However, many such programs are federally funded and are traditionally resource challenged.

Findings from this review led the authors to make several recommendations. First, PNSPs should be scaled up in accordance with expert guidance and should be customized appropriately to meet the needs of different prison populations, whereas monitoring and evaluation should be incorporated into the ongoing operation of PNSPs (50). Second, more research is needed on the effectiveness of PNSPs, and funders should make it a higher priority to support this work. Researchers should seek to identify innovative study designs that will overcome methodological limitations identified in this article. Research on PNSPs also needs to address questions relating to which service-delivery models are most suitable for different types of prison settings and populations and to better quantify the incidence of harmful effects of PNSPs such as increased drug use or needle-inflicted injuries. Third, the role of stigma in discouraging policy action on PNSPs should be addressed through multifaceted strategies, including education

framing the injecting of illegal drugs in the context of substance use disorders and by engaging with prison staff in the development of programs.

This study has several limitations. As noted previously, the low overall methodological quality of the studies that met review inclusion criteria limits their value as evidence of the effectiveness of PNSPs for achieving health benefits. Furthermore, the challenge of choosing a suitable study design for assessing PNSP outcomes is complicated by logistical and ethical considerations, including those related to PNSPs as a component of a comprehensive harm reduction package as well as to the conduct of research in incarcerated populations. Because the studies presented in this review took place in European countries, there may be publication bias. A lack of standardized definitions for health outcomes led the study team to develop its own definitions, which may have resulted in selection bias. Due to the diversity of study settings, findings cannot be generalized to all prisons, and variation may exist between prison subpopulations differentiated by sex, health status, drug consumption history, and other factors.

In conclusion, improvements in prison disease prevention ultimately will require systemic changes, including the strengthening of health systems as well as greater collaboration between ministries of justice, interior, and health. Winning greater support for PNSPs is not a simple undertaking, but it is essential for progressing toward major global targets in the fields of HIV and viral hepatitis (32, 51, 52). A less tangible but equally important benefit of getting PNSPs legitimized as a standard component of prison health care is that this will further affirm the health rights of people who inject drugs, opening the door to additional progress in reducing their marginalized status and improving their well-being.

ACKNOWLEDGMENTS

Author affiliations: Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (Jeffrey V. Lazarus, Kelly Safreed-Harmon, Kristina L. Hetherington); Barcelona Institute of Global Health, Hospital Clínic, University of Barcelona, Barcelona, Spain (Jeffrey V. Lazarus, Kelly Safreed-Harmon, Daniel J. Bromberg, Denise Ocampo); Institute of Addiction Research, Frankfurt University of Applied Sciences, Frankfurt, Germany (Neils Graf, Anna Dichtl, Heino Stöver); and Division of Prison Health, Geneva University Hospitals and University of Geneva, Geneva, Switzerland (Hans Wolff).

This research is part of the joint action 677085/HA-REACT, which has received funding from the European Union's Health Program (2014–2020).

Conflict of interest: none declared.

REFERENCES

1. World Health Organization. *Health Interventions for Prisoners: Update of the Literature Since 2007*. Geneva, Switzerland: World Health Organization; 2014. http://apps.who.int/iris/bitstream/10665/128116/1/WHO_HIV_2014.12_eng.pdf. Accessed March 18, 2018.

2. Jürgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. *Lancet Infect Dis*. 2009;9(1):57–66.
3. Boys A, Farrell M, Bebbington P, et al. Drug use and initiation in prison: results from a national prison survey in England and Wales. *Addiction*. 2002;97(12):1551–1560.
4. Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. *Lancet*. 2016;388(10049):1089–1102.
5. Larney S, Kopinski H, Beckwith CG, et al. The incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. *Hepatology*. 2013;58(4):1215–1224.
6. Treloar C, McCredie L, Lloyd AR. The prison economy of needles and syringes: what opportunities exist for blood borne virus risk reduction when prices are so high? *PLoS One*. 2016;11(9):e0162399.
7. Kamarulzaman A, Reid SE, Schwitters A, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. *Lancet*. 2016;388(10049):1115–1126.
8. World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Program on HIV/AIDS. *Interventions to Address HIV in Prisons: Needle and Syringe Programmes and Decontamination Strategies*. (Evidence for Action Technical Papers). Geneva, Switzerland: World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Program on HIV/AIDS; 2007. <https://www.unodc.org/documents/hiv-aids/EVIDENCE%20FOR%20ACTION%202007%20NSP.pdf>. Accessed March 18, 2018.
9. Buning EC. Effects of Amsterdam needle and syringe exchange. *Int J Addict*. 1991;26(12):1303–1311.
10. Des Jarlais DC, Mathilde Krim, amfAR, and the prevention of HIV infection among injecting drug users: a brief history. *AIDS Patient Care STDS*. 2006;20(7):467–471.
11. Fernandes RM, Cary M, Duarte G, et al. Effectiveness of needle and syringe programmes in people who inject drugs – an overview of systematic reviews. *BMC Public Health*. 2017;17(1):309.
12. Davis SM, Daily S, Kristjansson AL, et al. Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis. *Harm Reduct J*. 2017;14(1):25.
13. Platt L, Minozzi S, Reed J, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. *Addiction*. 2018;113(3):545–563.
14. World Health Organization. *WHO, UNODC, UNAIDS Technical Guide for Countries to Set Targets for Universal Access to HIV Prevention, Treatment and Care for Injecting Drug Users*. Geneva, Switzerland: World Health Organization; 2009. <http://www.who.int/hiv/pub/idu/targetsetting/en/>. Accessed March 18, 2018.
15. The International Network of People Who Use Drugs. *Consensus Statement on Drug Use Under Prohibition: Human Rights and the Law*. London, UK: The International Network of People Who Use Drugs; 2015. https://www.inpud.net/consensus_statement_2015.pdf. Accessed March 18, 2018.
16. International Centre for Science in Drug Policy. The Vienna Declaration. Organizational endorsements. http://www.who.int/iris/bitstream/10665/128116/1/WHO_HIV_2014.12_eng.pdf. Accessed March 18, 2018.

- viennadeclaration.com/organizational-endorsements/. Accessed September 8, 2017.
17. Stone K, Sander G. *The Global State of Harm Reduction*. London, UK: Harm Reduction International; 2016.
 18. United Nations General Assembly. Basic principles for the treatment of prisoners. Point 9 of Resolution A/RES/45/111 68th plenary meeting. New York, NY: United Nations General Assembly; 1990. <http://www.un.org/documents/ga/res/45/a45r111.htm>. Accessed May 6, 2017.
 19. Council of Europe Committee of Ministers. Recommendation No. R(93)6. Strasbourg, France: Council of Europe Committee of Ministers; 1993. [http://pjp-eu.coe.int/documents/3983922/6970334/CMRec+\(93\)+6+concerning+prison+and+criminological+aspects+of+the+control+of+transmissible+diseases+including+aids+and+related+health+problems+in+prison.pdf/942201cb-50f7-415c-8293-dda4d69f256d](http://pjp-eu.coe.int/documents/3983922/6970334/CMRec+(93)+6+concerning+prison+and+criminological+aspects+of+the+control+of+transmissible+diseases+including+aids+and+related+health+problems+in+prison.pdf/942201cb-50f7-415c-8293-dda4d69f256d). Accessed May 6, 2017.
 20. United Nations Office on Drugs and Crime. *Good Governance for Prison Health in the 21st Century: A Policy Brief on the Organization of Prison Health*. Vienna, Austria: United Nations Office on Drugs and Crime; 2013. http://www.euro.who.int/_data/assets/pdf_file/0017/231506/Good-governance-for-prison-health-in-the-21st-century.pdf?ua=1. Accessed March 18, 2018.
 21. World Medical Association General Assembly. *Declaration of Lisbon on the Rights of the Patient*. Ferney-Voltaire, France: World Medical Association; 2005. <http://dl.med.or.jp/dl-med/wma/libson2005e.pdf>. Accessed March 18, 2018.
 22. Nelles J, Harding T. Preventing HIV transmission in prison: a tale of medical disobedience and swiss pragmatism. *Lancet*. 1995;246(8989):1507–1508.
 23. Levy, M. Letter to Leon – a perspective from Australia. In: Stöver H, Knorr B, eds. *HIV und Hepatitis-Prävention in Haft – keine Angst vor Spritzen!* Oldenburg, Germany: BIS-Verlag; 2014:105.
 24. Dolan K, Rutter S, Wodak AD. Prison-based syringe exchange programmes: a review of international research and development. *Addiction*. 2003;98(2):153–158.
 25. Shahbazi M, Farnia M, Moradi G, et al. Injecting drug users retention in Needle-Exchange Program and its determinants in Iran prisons. *Int J High Risk Behav Addict*. 2015;4(2):e23751.
 26. The European Monitoring Centre for Drugs and Drug Addiction. *Harm Reduction Overview for Romania*. Lisbon, Portugal: The European Monitoring Centre for Drugs and Drug Addiction; 2015. <http://www.emcdda.europa.eu/country-data/harm-reduction/Romania>. Accessed May 6, 2017.
 27. World Health Organization. *WHO Guidelines on HIV Infection and AIDS in Prisons*. Geneva, Switzerland: World Health Organization; 1993. http://www.who.int/hiv/idu/WHO-Guidel-Prisons_en.pdf?ua=1. Accessed March 18, 2018.
 28. World Health Organization. *Effectiveness of Sterile Needle and Syringe Programming in Reducing HIV/AIDS Among Injecting Drug Users*. (Evidence for Action Technical Papers). Geneva, Switzerland: World Health Organization; 2004. http://www.who.int/hiv/pub/prev_care/en/effectivenesssterileneedle.pdf. Accessed March 18, 2018.
 29. Knight, L. *UNAIDS: The First 10 Years, 1996–2006*. Geneva, Switzerland: Joint United Nations Program on HIV/AIDS; 2008. http://data.unaids.org/pub/report/2008/jc1579_first_10_years_en.pdf. Accessed March 18, 2018.
 30. United Nations Program on HIV/AIDS. *UNAIDS 2016–2021 Strategy: On the Fast-Track to End AIDS*. 2015. http://www.unaids.org/sites/default/files/media_asset/20151027_UNAIDS_PCB37_15_18_EN_rev1.pdf. Accessed March 8, 2018.
 31. World Health Organization. *Global Health Sector Strategy on Viral Hepatitis, 2016–2021: Towards Ending Viral Hepatitis*. Geneva, Switzerland: World Health Organization; 2016.
 32. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2000;283(15):2008–2012.
 33. Ferrer-Castro V, Crespo-Leiro MR, García-Marcos LS, et al. [Evaluation of needle exchange program at Pereiro de Aguiar prison (Ourense, Spain): ten years of experience]. *Rev Esp Sanid Penit*. 2012;14(1):3–11.
 34. Heinemann A, Gross U. Prevention of blood-borne virus infections among drug users in an open prison by vending machines. *Sucht*. 2001;47(1):57–65.
 35. Jacob J, Stöver H. The transfer of harm-reduction strategies into prisons: needle exchange programmes in two German prisons. *Int J Drug Policy*. 2000;11(5):325–335.
 36. Meyenberg R, Stöver H, Jacob J, et al. (1996–1999): Infektionsprophylaxe im Niedersächsischen Justizvollzug – Eröffnungsbericht. Bd. 1–3 der Schriftenreihe “Gesundheitsförderung im Justizvollzug”. Volume 1–3. 1996. <http://oops.uni-oldenburg.de/683/1/716.pdf>. Accessed March 11, 2017.
 37. Nelles J, Fuhrer A, Hirsbrunner HP, et al. Provision of syringes: the cutting edge of harm reduction in prison? *BMJ*. 1998;317(7153):270–273.
 38. Stark K, Herrmann U, Ehrhardt S, et al. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany. *Epidemiol Infect*. 2006;134(4):814–819.
 39. United Nations Office on Drugs and Crime, International Labor Organization, United Nations Development Program. *HIV Prevention, Treatment and Care in Prisons and Other Closed Settings: A Comprehensive Package of Interventions*. Vienna, Austria: United Nations Office on Drugs and Crime; 2012. https://www.unodc.org/documents/hiv-aids/HIV_prisons_advance_copy_july_2012_leaflet_UNODC_ILO_UNDP_Ebook.pdf. Accessed May 6, 2017.
 40. United Nations Program on HIV/AIDS. *Evaluation of the 100% Condom Programme in Thailand: UNAIDS Case Study*. Geneva, Switzerland: United Nations Program on AIDS; 2000. http://data.unaids.org/publications/irc-pub01/jc275-100pcondom_en.pdf. Accessed March 18, 2018.
 41. Levine R. *Case Studies in Global Health: Millions Saved*. Sudbury, MA: Jones and Bartlett Publishers; 2004.
 42. Wodak A, Cooney A. Effectiveness of sterile needle and syringe programmes. *Int J Drug Policy*. 2005;16(1):31–44.
 43. Stöver H, Nelles J. Ten years of experience with needle and syringe exchange programmes in European prisons. *Int J Drug Policy*. 2003;14(5–6):437–444.
 44. Menoyo C, Zulaica D, Parras F. Needle exchange programs in prisons in Spain. *Can HIV AIDS Policy Law Rev*. 2000;5(4):20–21.
 45. Lines R, Jürgens R, Betteridge G, et al. Taking action to reduce injecting drug-related harms in prisons: the evidence of effectiveness of prison needle exchange in six countries. *Int J Prisoner Health*. 2005;1(1):49–64.
 46. Doerrbecker J, Friesland M, Ciesek S, et al. Inactivation and survival of hepatitis C virus on inanimate surfaces. *J Infect Dis*. 2011;204(12):1830–1838.
 47. Ciesek S, Friesland M, Steinmann J, et al. How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. *J Infect Dis*. 2010;201(12):1859–1866.

48. Stöver, H, Hariga, F. Prison-based needle and syringe programmes (PNSP) – still highly controversial after all these years. *Drugs Educ Prev Policy*. 2016;23(2):103–112.
49. Bridge J, Hunter BM, Albers E, et al. The Global Fund to Fight AIDS, Tuberculosis and Malaria's investments in harm reduction through the rounds-based funding model (2002–2014). *Int J Drug Policy*. 2016;27:132–137.
50. United Nations Office on Drugs and Crime. *A Handbook for Starting and Managing Needle and Syringe Programmes in Prisons and Other Closed Settings*. Vienna, Austria: United Nations Office on Drugs and Crime; 2014. https://www.unodc.org/documents/hiv-aids/2017/ADV_PNSP_REV_FEB2015with_cover1.pdf. Accessed March 18, 2018.
51. World Health Organization. *Global Health Sector Strategy on HIV, 2016–2021: Towards Ending AIDS*. Geneva, Switzerland: World Health Organization; 2016. <http://apps.who.int/iris/bitstream/10665/246178/1/WHO-HIV-2016.05-eng.pdf?ua=1>. Accessed March 18, 2018.
52. United Nations Department of Economic and Social Affairs. *Sustainable Development Knowledge Platform*. New York, NY: United Nations; 2015. <https://sustainabledevelopment.un.org>. Accessed September 8, 2017.